Insider Selling: Amarin Co. plc (AMRN) Insider Sells $284,605.20 in Stock

Amarin Co. plc (NASDAQ:AMRN) insider Steven B. Ketchum sold 64,683 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $4.40, for a total value of $284,605.20. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of Amarin Co. plc (NASDAQ AMRN) opened at $4.30 on Friday. The company has a market capitalization of $1,160.00, a price-to-earnings ratio of -15.93 and a beta of 0.62. The company has a quick ratio of 1.32, a current ratio of 1.63 and a debt-to-equity ratio of -1.48. Amarin Co. plc has a 12-month low of $2.81 and a 12-month high of $4.47.

Amarin (NASDAQ:AMRN) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $47.10 million during the quarter, compared to analyst estimates of $45.85 million. The business’s quarterly revenue was up 45.4% on a year-over-year basis. During the same period last year, the business earned ($0.08) EPS. research analysts expect that Amarin Co. plc will post -0.22 EPS for the current year.

Several analysts have recently commented on AMRN shares. Cantor Fitzgerald set a $10.00 target price on Amarin and gave the stock a “buy” rating in a research report on Thursday, January 4th. Zacks Investment Research raised Amarin from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. BidaskClub raised Amarin from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Finally, ValuEngine raised Amarin from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Amarin currently has a consensus rating of “Buy” and an average price target of $7.75.

Several institutional investors have recently modified their holdings of the company. Alkeon Capital Management LLC acquired a new stake in shares of Amarin in the third quarter worth $7,875,000. University of Notre Dame DU Lac acquired a new stake in Amarin during the third quarter valued at $2,814,000. GSA Capital Partners LLP boosted its position in Amarin by 135.4% during the second quarter. GSA Capital Partners LLP now owns 342,800 shares of the biopharmaceutical company’s stock valued at $1,381,000 after purchasing an additional 197,200 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Amarin by 681.5% during the second quarter. JPMorgan Chase & Co. now owns 278,134 shares of the biopharmaceutical company’s stock valued at $1,121,000 after purchasing an additional 242,544 shares during the last quarter. Finally, State Street Corp boosted its position in Amarin by 1.3% during the second quarter. State Street Corp now owns 201,995 shares of the biopharmaceutical company’s stock valued at $814,000 after purchasing an additional 2,640 shares during the last quarter. 40.12% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Amarin Co. plc (AMRN) Insider Sells $284,605.20 in Stock” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/12/insider-selling-amarin-co-plc-amrn-insider-sells-284605-20-in-stock.html.

About Amarin

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply